丹磺酰化氨基酸修饰的长效PSMA衍生物68Ga/177Lu-LNC1011用于前列腺癌诊疗一体化
本研究合成三种丹磺酰化氨基酸修饰的新型PSMA配体,其中[68Ga]Ga-LNC1011在PC3-PIP荷瘤鼠中肿瘤/心、肝、肾、肌肉比值分别为9.82±2.35、12.42±3.71、4.36±0.29、52.88±12.08(注射后4小时)。[177Lu]Lu-LNC1011注射后4小时肿瘤摄取为127.36±16.95 %ID/g,高于[177Lu]Lu-PSMA-617的17.44±6.29 %ID/g,且至72小时未下降。单次注射9.3 MBq的[177Lu]Lu-LNC1011抑瘤率达89.43%,与18.5 MBq的[177Lu]Lu-PSMA-617(90.87%)相当。[68Ga]Ga-LNC1011 PET/CT在转移性去势抵抗性前列腺癌患者中检出的病灶数与[68Ga]Ga-PSMA-11相同。
要点
- 三种新型PSMA配体放射化学产率均大于97%。
- [177Lu]Lu-LNC1011注射后4小时肿瘤摄取127.36±16.95 %ID/g,高于[177Lu]Lu-PSMA-617的17.44±6.29 %ID/g。
- 单次9.3 MBq [177Lu]Lu-LNC1011抑瘤率89.43%,与18.5 MBq [177Lu]Lu-PSMA-617的90.87%相当。
核心结论
- 68Ga/177Lu-LNC1011具有高肿瘤摄取和滞留、正常器官组织及时清除的特点,是一种有前景的单分子诊疗一体化放射性配体。
研究设计与样本
- 本研究合成三种丹磺酰化氨基酸修饰的新型PSMA配体,通过超滤实验测定与人血清白蛋白的结合特性,用饱和结合实验和PC3-PIP细胞摄取评估结合亲和力与PSMA靶向特异性,并在PC3-PIP荷瘤鼠中进行PET显像、SPECT/CT显像、生物分布和放射性药物治疗研究。
主要发现
- 三种新型PSMA配体([68Ga]Ga-Dan-Gly-PSMA、[68Ga]Ga-Dan-Nva-PSMA和[68Ga]Ga-LNC1011)放射化学产率均大于97%。
- PC3-PIP荷瘤鼠注射后4小时肿瘤/心、肿瘤/肝、肿瘤/肾、肿瘤/肌肉比值分别为9.82±2.35、12.42±3.71、4.36±0.29、52.88±12.08。
- 生物分布研究显示注射后4小时[177Lu]Lu-LNC1011肿瘤摄取为127.36±16.95 %ID/g,高于[177Lu]Lu-PSMA-617的17.44±6.29 %ID/g,且[177Lu]Lu-LNC1011至注射后72小时未见下降,SPECT显像证实该结果。
- 单次注射9.3 MBq的[177Lu]Lu-LNC1011抑瘤率达89.43%,与18.5 MBq的[177Lu]Lu-PSMA-617(90.87%)相当。
- [68Ga]Ga-LNC1011 PET/CT在转移性去势抵抗性前列腺癌患者中检出的病灶数与[68Ga]Ga-PSMA-11相同,证实其诊断效能。
关键数值与推荐
- 三种新型PSMA配体放射化学产率大于97%。
- PC3-PIP荷瘤鼠注射后4小时肿瘤/心、肿瘤/肝、肿瘤/肾、肿瘤/肌肉比值分别为9.82±2.35、12.42±3.71、4.36±0.29、52.88±12.08。
- 注射后4小时[177Lu]Lu-LNC1011肿瘤摄取127.36±16.95 %ID/g,[177Lu]Lu-PSMA-617为17.44±6.29 %ID/g。
- 单次9.3 MBq [177Lu]Lu-LNC1011抑瘤率89.43%,18.5 MBq [177Lu]Lu-PSMA-617抑瘤率90.87%。
- [68Ga]Ga-LNC1011 PET/CT检出的病灶数与[68Ga]Ga-PSMA-11相同。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy has demonstrated promising potential for treating metastatic castration-resistant prostate cancer. Recently, albumin-binding motif-modified PSMA radioligands with prolonged blood circulation were developed to improve tumor uptake and therapeutic effectiveness, properties which, however, were associated with an increased risk of bone marrow toxicity. This study presents new PSMA-targeted radioligands incorporating dansylated amino acids as relatively weak and preferable albumin binders to achieve a fine balance between increased tumor accumulation, safety, and diagnostic efficacy, facilitating a unified approach to theranostics within a single molecular framework. Methods: Three novel PSMA ligands ([68Ga]Ga-Dan-Gly-PSMA, [68Ga]Ga-Dan-Nva-PSMA, and [68Ga]Ga-Dan-Phe-PSMA, denoted as [68Ga]Ga-LNC1011) were synthesized with dansylated amino acids and measured the albumin-binding properties with human serum albumin through ultrafiltration experiments. Binding affinity and PSMA-targeting specificity were investigated using a saturation binding assay and cell uptake in the PSMA-induced prostate cancer 3 cell line (PC3-PIP). PET imaging in PC3-PIP tumor-bearing mice was performed to evaluate the preclinical pharmacokinetics and diagnostic efficiency of 68Ga-labeled PSMA ligands. Tumor uptake of [177Lu]Lu-LNC1011 was evaluated through SPECT/CT imaging and biodistribution studies. Radiopharmaceutical therapy studies were conducted to systematically assess the therapeutic effect of the radioligand. Results: Three novel PSMA radioligands ([68Ga]Ga-Dan-Gly-PSMA, [68Ga]Ga-Dan-Nva-PSMA, and [68Ga]Ga-LNC1011) with various dansylated amino acids were successfully synthesized with a radiochemical yield greater than 97%. In the PC3-PIP xenograft tumor model, the tumor/heart, tumor/liver, tumor/kidney, and tumor/muscle ratios were 9.82 ± 2.35, 12.42 ± 3.71, 4.36 ± 0.29, and 52.88 ± 12.08 at 4 h after injection, respectively. Biodistribution studies confirmed the significantly higher tumor uptake of [177Lu]Lu-LNC1011 (127.36 ± 16.95 %ID/g) over [177Lu]Lu-PSMA-617 (17.44 ± 6.29 %ID/g) at 4 h after injection, and no decrease was measured for the [177Lu]Lu-LNC1011 at up to 72 h after injection, which was corroborated with SPECT imaging. A single injection of 9.3 MBq of [177Lu]Lu-LNC1011 achieved 89.43% inhibition of tumor growth, equivalent to 18.5 MBq of [177Lu]Lu-PSMA-617 (90.87%). [68Ga]Ga-LNC1011 PET/CT scans of patients with metastatic castration-resistant prostate cancer identified as many lesions as [68Ga]Ga-PSMA-11 did, confirming its diagnostic efficacy. Conclusion: 68Ga/177Lu-LNC1011, characterized by high tumor uptake and retention along with timely clearance from normal organs and tissues, thus emerges as a promising single-molecule theranostic radioligand.
引用
- Yang H, Wang J, Wen X, et al. Dansylated Amino Acid-Modified Long-Acting PSMA Derivatives 68Ga/177Lu-LNC1011 as Prostate Cancer Theranostics. J Nucl Med. 2025. PMID: 40113222. doi:10.2967/jnumed.124.268959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。